Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

RXi Pharmaceuticals logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Advanced Chart

Key Stats

Today's Range
$2.51
$3.48
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
49.54 million shs
Average Volume
1.73 million shs
Market Capitalization
$12.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
Is this the biggest winner of Trump’s tariffs?
America’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has already been pledged to restore U.S. manufacturing. Trump’s tariffs and trade pressure have set off a massive reshoring push, and the flood of investment is still gaining steam. But while everyone’s watching the big names, one under-the-radar company holds the key tech that could make it all work — and potentially benefit the most.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines

RXII Stock Analysis - Frequently Asked Questions

RXi Pharmaceuticals Co. (NASDAQ:RXII) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company earned $0.06 million during the quarter, compared to the consensus estimate of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%.

RXi Pharmaceuticals's stock reverse split on Monday, January 8th 2018.The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Endologix (ELGX), Auris Medical (EARS), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
8/14/2018
Today
7/26/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RXII
CIK
1533040
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.45 million
Net Margins
-4,990.20%
Pretax Margin
N/A
Return on Equity
-412.15%
Return on Assets
-179.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.77
Quick Ratio
1.77

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
1,200.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
3.56

Miscellaneous

Outstanding Shares
4,380,000
Free Float
N/A
Market Cap
$12.00 million
Optionable
Not Optionable
Beta
2.07
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:RXII) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners